Preparation and usage of plasmodium fusion antigen

Details Preparation and usage of plasmodium fusion antigen Preparation and usage of plasmodium fusion antigen

2006-09-05

2006-09-05

Minnifield, N. M. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S184100, C424S185100, C424S192100, C424S193100, C424S265100, C424S268100, C424S266100, C424S272100, C530S300000, C530S350000, C435S320100, C435S252100, C536S023100, C536S023600

Reexamination Certificate

active

07101556

ABSTRACT:
The invention provides a fusion protein comprising thePlasmodiummerozoite surface protein-1 (MSP1) and thePlasmodiumapical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1/MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response againstPlasmodiumin individuals.

REFERENCES:
patent: 4643896 (1987-02-01), Asakura et al.
patent: 5185146 (1993-02-01), Altenburger
patent: 5229110 (1993-07-01), DuBois et al.
patent: 5720959 (1998-02-01), Holder et al.
patent: 5766597 (1998-06-01), Paoletti et al.
patent: 5814617 (1998-09-01), Hoffman et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6551586 (2003-04-01), Davidson et al.
patent: 6593463 (2003-07-01), Chen et al.
patent: 6669945 (2003-12-01), Nardin et al.
patent: 6855322 (2005-02-01), Lyon et al.
patent: 6933130 (2005-08-01), Bujard et al.
patent: 2003/0032787 (2003-02-01), Lanar et al.
patent: 2004/0063190 (2004-04-01), Pan
patent: 2004/0091971 (2004-05-01), Kocken et al.
patent: 2005/0208068 (2005-09-01), Milich et al.
patent: 2006/0018911 (2006-01-01), Ault-Riche et al.
patent: 2006/0018932 (2006-01-01), Longacre-Andre et al.
patent: 1357128 (2003-10-01), None
patent: WO 95/21192 (1995-08-01), None
patent: WO 98/14583 (1998-04-01), None
patent: WO 00/63245 (2000-10-01), None
patent: WO 02/72625 (2002-09-01), None
Zhang et al, Shengwu Huaxue Yu Shengu Wuli Xuebao, 2003, 35/4:345-349 Abstract Only.
Ming et al, Chinese medical Journal, Aug. 1999, 112/8:691-697 Abstract Only.
Enders et al, Mem. Inst. Oswaldo Cruz, 1992, 87/Suppl. 3:413-422 Abstract Only.
Sallberg et al, Intervirology, 2002, 45/4-6:350-361 Abstract Only.
Burns et al, Vaccine, May 2003, 21/17-18:1843-1852 Abstract Only.
Anders et al, Vaccine, 1998, 16/2-3:240-247 Abstract Only.
Patarroyo et al, Nature, 1987, 328:629-632.
Peterson et al, Molecular and Cellular Biology, 1989, 9/7:3151-3154.
Stoute et al, New England J. Medicine, 1997, 336:86-91.
Gardner et al, Nature, 2002, 419:498-511.
Marshall et al, Molecular and Biochemical Parasitology, 1996, 11:109-113.
Kester et al, J. Infectious Diseases, 2001, 183:640-647.
Lalvani et al, J. Infectious Diseases, 1999, 180:1656-1664.
Jones et al, Vaccine, 1999, 17:3065-3071.
Bojang et al, lancet, 2001, 358:1927-1934.
Garcon et al, Expert Rev. Vaccines, 2003, 2/2:231-238.
Kim et al, Korean J. Parasitology, 2003, 41/4:203-207.
Stowers et al, Infection and Immunity, 2001, 69/3:1536-1546.
Daly et al, infection and Immunity, 1996, 64/7:2602-2608.
Kang et al, J. Immunology, 1998, 161:4211-4219.
Pan et al, Nucleic Acids Research, 1999, 27/4:1094-1103.
Adda et al, Infection and Immunity, 1999, 67/9:4679-4688.
Ahlborg et al, Infection and Immunity, 2002, 70/2:820-825.
Fries et al, PNAS USA, 1992, 89:358-362.
Kim et al, Yonsei Medical Journal, 2004, 45/1:129-134.
Perraut et al, Infection and Immunity, 1995, 63/2:554-562.
Ramasamy et al, BBA, 1999, 1453:1-13.
Carucci, Vaccine, 2001, 19:2315-2318.
Smooker et al, Vaccine, 2000, 18:2533-2540.
Gilbert et al, Parasitology Today, 1997, 13/8:302-306.
Nacher, TRENDS in Parasitology, 2001, 17/12:563-565.
Butcher et al, Parasitology Today, 2000, 16/2:43-44.
Taylor-Robinson, TRENDS in Microbiology, 1999, 7/1:15.
Senoir, Molecular Medicine Today, Jan. 1999, pp. 2-3.
Doolan et al, Parasitology Today, 1997, 13/5:171-178.
Plebanski et al, Current Opinion in Immunology, 2000, 12:437-441.
Jones et al, Vaccine, 2002, 20:1675-1680.
Arevalo-Herrera et al, Molecular Immunology, 2001, 38:443-455.
Uhlemann et al, Molecular and Biochemical Parasitology, 2001, 118:41-48.
Stowers et al, TRENDS in Parasitology, 2001, 17/9:415-419.
Heppner et al, TRENDS in Parasitology, 2001, 17/9:419-425.
Anders et al, Parasitology Today, 2000, 16/10:444-447.
Tatsis et al, Molecular Therapy, 2004, 10/4:616-629.
Barnwell et al, Experimental Parasitology, 1999, 91:238-249.
Hommel et al, Parasitology Today, 1998, 14/9:337-340.
Galinski et al, Parasitology Today, 1996, 12/1:20-29.
Herrera et al, International J. Parasitology, 2002, 32:1625-1635.
Epstein et al, Vaccine, 2004, 22:1592-1603.
Zhou et al, Protein Expression and Purification, 2004, 34:87-94.
Rogers et al, Vaccine, 1999, 17:3136-3144.
Shi et al, Vaccine, 2000, 18:2902-2914.
Rafi-Janajreh et al, Experimental Parasitology, 2002, 101:3-12.
Doolan et al, international J. parasitology, 2001, 31:753-762.
Cox, Nature, 1992, 360:417-418.
Kurtis et al, Infection and Immunity, 1999, 67/7:3424-3429.
Joshi et al, Infection and Immunity, 2000, 68/1:141-150.
Kurtis et al, TRENDS in Parasitology, 2001, 17/5:219-223.
Shi et al, PNAS USA, 1999, 96:1615-1620.
Ntumngia et al, Molecular and Biochemical Parasitology, 2004, 137:349-353.
Ballou et al, Am. J. Trop. Med. Hyg., 2004, 71/Suppl. 2:239-247.
Moorthy et al, Lancet, 2004, 363/9403:150-156 Abstract only.
Wu et al, J. Biotechnology, 2000, 83:125-135.
Pan et al, J. Immunology, 2004, 172:6167-6174.
Healer et al, Infection and Immunity, Apr. 2005, 73/4:2444-2451.
Pedro L. Alonso, et al., “Efficacy of the RTS,S/AS02A Vaccine Against Plasmodium Falciparum Infection and Disease in Young African Children: Randomised Controlled Trial”, www.thelacncet.com, vol. 364, Oct. 16, 2004, pp. 1411-1420.
W. Ripley Ballou et al., “Update on the Clinical Development of Candidate Malaria Vaccines”, Am. J. Trop. Med. Hyg., 71(Suppl 2), 2004, pp. 239-247.
Sandra P. Chang, et al., “A Recombinant Baculovirus 42-Kilodalton C-Terminal Fragment of Plasmodium Falciparum Merozoite Surface Protein 1 Protects Aotus Monkeys against Malaria”, Infection and Immunity, vol. 64, No. 1, Jan. 1996, pp. 253-261.
George S. N. Hui, et al., “Research Brief: Serum from Pf195 Protected Aotus Monkeys Inhibit Plasmodium Falciparum Growth in Vitro”, Experimental Parasitology, 64, 519-522 (1987).

Affiliated with

Also associated with

Rating

Preparation and usage of plasmodium fusion antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation and usage of plasmodium fusion antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and usage of plasmodium fusion antigen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3552480